3.8 Article

A clinical model to predict fibrosis on liver biopsy in paediatric subjects with nonalcoholic fatty liver disease

Journal

CLINICAL OBESITY
Volume 11, Issue 5, Pages -

Publisher

WILEY
DOI: 10.1111/cob.12472

Keywords

fibrosis; hepatitis; liver; obesity; predictive-model; steatosis

Funding

  1. American Gastroenterological Foundation [NIH K08 DK 122018 01]
  2. Doris Duke Charitable Foundation

Ask authors/readers for more resources

The study aimed to identify non-invasive parameters to predict advanced NAFLD and fibrosis in children, finding correlations between platelets, gender, GGT, etc. with NAFLD and fibrosis. They established a multivariate logistic regression-based scoring system to identify high-risk patients for expedited biopsy.
The incidence of nonalcoholic fatty liver disease (NAFLD) in children is rapidly increasing. Liver fibrosis is a poor prognostic feature that independently predicts cirrhosis. The time that intercedes the first medical encounter and biopsy is rate-limiting to multi-modal treatment. This study aimed to identify non-invasive parameters to predict advanced NAFLD and fibrosis. We conducted a single-center, retrospective 10-year analysis of 640 paediatric patients who underwent liver biopsy. 55 patients, age 3-21 years, had biopsy-confirmed NAFLD. We assessed primary outcomes, NAFLD activity score (NAS) and fibrosis scores, against non-invasive parameters by linear regression, by using binary cutoff values, and by a multivariate logistic regression fibrosis prediction model. NAS correlated with platelets and female sex. Fibrosis scores correlated with platelet counts, gamma glutamyl transferase (GGT), and ultrasound shear wave velocity. 25-hydroxy-vitamin D and GGT differentiated mild versus moderate-to-advanced fibrosis. Our multivariate logistical regression model-based scoring system predicted F2 or higher (parameters: BMI%, vitamin D, platelets, GGT), with sensitivity and specificity of 0.83 and 0.95 (area under the ROC curve, 0.944). We identify a clinical model to identify high-risk patients for expedited biopsy. Stratifying patients to abbreviate time-to-biopsy can attenuate delays in aggressive therapy for high-risk patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available